

PolyPhil™ hair

Injectable Polynucleotides

Minimally invasive aesthetic treatment for promoting trophic action and hair growth

Indicated areas:

- Scalp¹
- Arches of the eyebrows¹
- Sensitive skin and delicate areas²

Purpose:

#1 A standalone treatment to support revitalisation of the hair follicles resulting in **promotion and acceleration of the hair growth.**²

SET Skin Enhancement Technique (SET) to generate synergistic effect and enhance treatment benefits in combination with other interventions (biotin, hyaluronic acid, carboxytherapy, topical therapy)² and as adjuvant post-surgery treatment after hair transplantation.³

Injection protocol and injection technique:²

Treatment	Suggested protocol	Injection technique
Promoting trophic action and hair growth	Initial treatment cycle: one session every 7 or 14 days for a total of 4 sessions Suggested maintenance: Followed by one session every 21–30 days for further 4 sessions.	Needle microdroplets technique



Scalp, eyebrows and delicate areas



Concentration: 15 mg/2 ml | **Pack:** 1 x 2 ml pre-filled syringe
Needle: 2 x 30G x 1/2, 13 mm | **Depth of injection:** intradermal

Clinically proven safety and efficacy

of the PN-HPT™ for trophic stimulation of the scalp to promote hair growth in cases of female hormonal hair loss.³


Patients: 20 female patients aged between 25 and 65 years suffering from non-androgen-dependent female hormonal alopecia.

Protocol: PN-HPT™ administered with 2 ml pre-filled syringe containing 15 mg of PN-HPT™. Microdroplet technique with intradermal infiltrations of 0,2 ml for each drop. First month: one per week for 4 weeks, second, 3rd and 4th month: infiltration every 2–3 weeks.



Clinical evaluation: T0, T1, T2, T4 months

Results: the female alopecia objectively improved in **72 % of treated women with no side effects and high patient's compliance.**

Pull test demonstrated reduction in the number of lost hairs.



Improvement of trichogram values with hair increase in anagen (growing phase) and hair reduction in Telogen (resting phase).



Video dermoscopy demonstrated an increase in the number of average number of hairs in a standard area before and after treatment (T0 vs 4 months)

A) Baseline assessment (T0, 105 hairs/cm²);
B) end of study period (T12, 118 hairs/cm²)

¹ IFU PolyPhil hair | ² Cavallini M, Bartoletti E, Maioli L, Massirone A, Pia Palmieri I, Papagni M et al. Consensus report on the use of PN-HPT™ (polynucleotides highly purified technology) in aesthetic medicine. J Cosmet Dermatol. 2021 Mar;20(3):922-928. doi: 10.1111/jocd.13679. Epub 2020 Sep 21. PMID: 32799391; PMCID: PMC7984045. | ³ Lotti T, Gianfaldoni R, Gianfaldoni S, Nannipieri A. A polynucleotidebased product to treat female hormonal hair loss. Prime Journal 2014; 5(4):2-10.



The medical practitioner confirms having informed the patient of a likely risk associated with the use of the medical device in line with its intended use. For risks and adverse events associated with the use of the product consult the instructions of use.